Endo Health Solutions (NSDQ:ENDP) said it’s selling its HealthTronics urology business to Altaris Capital Partners for up to $130 million, including milestones.

Altaris, a private equity shop based in New York, will put down $85 million right away, with another $45 million on the line "based on the future operating performance of HealthTronics," according to a press release.

"The divestiture of HealthTronics enables us to focus more sharply on achieving our objective of building Endo into a leading product-based specialty healthcare company. I am pleased that the agreement with Altaris will provide an opportunity for the employees of HealthTronics to join an organization that will focus on growing this leading provider of products and services to U.S.-based Urologists," Endo president and CEO Rajiv De Silva said in prepared remarks.

Endo’s American Medical Systems subsidiary won 510(k) clearance for its RetroArc retropubic sling system last December. The device, for the treatment of female stress urinary incontinence, also won CE Mark approval in the European Union in December.